Patents by Inventor Christian Gege

Christian Gege has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220242858
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: January 11, 2022
    Publication date: August 4, 2022
    Inventors: Peter A. Blomgren, Kevin S. Currie, Julie Farand, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Publication number: 20220204460
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: November 29, 2021
    Publication date: June 30, 2022
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Publication number: 20220152008
    Abstract: The present invention relates to novel antiviral compounds with specific stereoconfiguration, especially to specific novel enantiomers, to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 19, 2022
    Inventors: Gerald Kleymann, Christian Gege
  • Patent number: 11278534
    Abstract: The present invention relates to novel antiviral compounds with specific stereoconfiguration, especially to specific novel enantiomers, to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: March 22, 2022
    Assignee: Innovative Molecules GmbG
    Inventors: Gerald Kleymann, Christian Gege
  • Patent number: 11247986
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 15, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Julie Farand, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Publication number: 20210401810
    Abstract: The present invention relates to the novel use of antiviral compounds, which act as helicase primase inhibitors in a combination therapy with oncolytic viruses for treating tumors, cancer or neoplasia.
    Type: Application
    Filed: November 27, 2019
    Publication date: December 30, 2021
    Inventors: Gerald Kleymann, Christian Gege
  • Publication number: 20210323995
    Abstract: The present invention relates to isolithocholic acid (3ß-hydroxy-5ß-cholan-24-oic acid, iso-LCA) and isoallolithocholic acid (3ß-hydroxy-5?-cholan-24-oic acid) and their deuterated analogs for preventing or treating Clostridium difficile-associated disease in a mammalian subject.
    Type: Application
    Filed: August 8, 2019
    Publication date: October 21, 2021
    Applicant: PHENEX PHARMACEUTICALS AG
    Inventors: Christian Gege, Manfred Birkel, Thomas Hoffman
  • Publication number: 20210147398
    Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXR? and/or LXK?) and act preferably as inverse agonists of LXR.
    Type: Application
    Filed: June 28, 2019
    Publication date: May 20, 2021
    Applicant: Phenex-FXR GmbH
    Inventors: Christian Gege, Olaf Kinzel, Eva Hambruch, Manfred Birkel, Claus Kremoser, Ulrich Deuschle
  • Publication number: 20200369632
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: August 10, 2020
    Publication date: November 26, 2020
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Publication number: 20200289486
    Abstract: The present invention relates to novel antiviral compounds with specific stereoconfiguration, especially to specific novel enantiomers, to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.
    Type: Application
    Filed: October 4, 2018
    Publication date: September 17, 2020
    Inventors: Gerald Kleymann, Christian Gege
  • Patent number: 10774054
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: September 15, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Publication number: 20200148652
    Abstract: The invention relates to novel compounds of the Formula (I) to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.
    Type: Application
    Filed: January 20, 2020
    Publication date: May 14, 2020
    Inventors: Gerald Kleymann, Christian Gege
  • Publication number: 20200131144
    Abstract: The present invention relates to derivatives of formula (I) which bind to the liver X receptor (LXR? and/or LXR?) and act preferably as inverse agonists of LXR.
    Type: Application
    Filed: July 18, 2018
    Publication date: April 30, 2020
    Applicant: Phenex-FXR GmbH
    Inventors: Christian Gege, Manfred Birkel, Eva Hambruch, Ulrich Deuschle, Claus Kremoser
  • Publication number: 20200115357
    Abstract: The present invention relates to sulfonamide-, sulfinamide- or sulfonimidamide containing compounds which bind to the liver X receptor (LXRa and/or LXR?) and act preferably as inverse agonists of LXR.
    Type: Application
    Filed: April 10, 2018
    Publication date: April 16, 2020
    Applicant: Phenex-FXR GmbH
    Inventors: Christian Gege, Manfred Birkel, Eva Hambruch, Ulrich Deuschle, Claus Kremoser
  • Patent number: 10590094
    Abstract: The invention relates to novel compounds of the Formula (I), to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: March 17, 2020
    Assignee: Innovative Molecules GmbH
    Inventors: Gerald Kleymann, Christian Gege
  • Publication number: 20200071282
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: August 14, 2019
    Publication date: March 5, 2020
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Publication number: 20190315729
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: May 10, 2019
    Publication date: October 17, 2019
    Inventors: Peter A. Blomgren, Kevin S. Currie, Julie Farand, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Publication number: 20190308962
    Abstract: The present disclosure relates generally to compounds (I) which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: June 9, 2017
    Publication date: October 10, 2019
    Applicant: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Patent number: 10421730
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: September 24, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Patent number: 10329286
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: June 25, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Julie Farand, Christian Gege, Jeffrey E. Kropf, Jianjun Xu